Experimental mRNA nasal drops developed by Australian researchers rejuvenate aged mouse brains and protect against Alzheimer’s symptoms by prompting the nasal mucosa to self-produce the protective protein BDNF, according to reports published by Berliner Morgenpost and other regional outlets.
Nasal mRNA Drops Restore Cognition in Older Mice
- The Delivery Route: Researchers used nasal drops containing messenger RNA (mRNA) wrapped in tiny fat particles to bypass the blood-brain barrier without surgery.
- The Cellular Action: Instead of delivering fragile proteins that degrade too quickly, the mRNA instructs cells in the nasal lining to manufacture brain-derived neurotrophic factor (BDNF), which then travels along nerve pathways into the brain.
- The Observed Effect: Tests on older mice showed cognitive performance restored to juvenile levels and a 2.4-fold increase in markers for young, immature neurons in the hippocampus, though no reduction in amyloid plaques was observed.
Overcoming the Blood-Brain Barrier via the Nasal Mucosa
The nasal mucosa serves as a potential key for accessing the central nervous system while bypassing the blood-brain barrier, Berliner Morgenpost reported. This natural physiological shield prevents numerous circulating pharmacological agents from passing out of the bloodstream and entering brain tissue.
Scientists have historically faced severe hurdles in delivering therapeutics past this protective wall without invasive surgical interventions. Many therapeutic compounds simply cannot cross the endothelium, while pre-manufactured protective proteins administered nasally are frequently degraded by mucosal enzymes before they can exert any biological activity.
To circumvent these biochemical roadblocks, a team led by Professor Greg Neely at the University of Sydney engineered experimental nasal drops, Berliner Morgenpost and its syndicate partners noted, according to Tlz.
These lipid-encapsulated formulations contain mRNA designed to serve as a cellular blueprint. Cells within the nasal epithelium take up this genetic instruction and synthesize brain-derived neurotrophic factor (BDNF) endogenously. The locally produced protein subsequently migrates via neural pathways directly into cerebral structures.
Cognitive Restoration and Neurogenesis in Aged Rodent Models
In evaluation trials, the research group administered the novel formulation to 18-month-old mice a total of four times, spaced at weekly intervals, Berliner Morgenpost detailed. Subsequent behavioral testing evaluating spatial memory, working memory, and object recognition revealed profound cognitive gains.
The cognitive capabilities of the aged cohort matched those of three-month-old young control animals. Professor Greg Neely stated, “Bei alten Mäusen beobachteten wir eine deutliche Verbesserung von Lernen und Gedächtnis, sodass ihre geistige Leistungsfähigkeit wieder das Niveau ihrer Jugend erreichte”, as reported by Berliner Morgenpost.

Histological examinations of the hippocampus demonstrated that treated subjects possessed approximately 2.4 times as many cells bearing markers characteristic of young, immature neurons. This cellular proliferation points toward an active stimulation of neurogenesis—the birth of new nerve cells—following the administration protocol.
In a parallel arm of the investigation involving genetically modified murine models predisposed to early-onset Alzheimer’s symptoms, twice-weekly administration starting at two months of age successfully prevented the typical cognitive decline.
| Parameter | Aged Wild-Type Mice (18 Months) | Alzheimer’s Model Mice |
|---|---|---|
| Treatment Regimen | Four doses, once weekly | Twice weekly starting at age two months |
| Observed Cognitive Outcome | Cognition restored to three-month-old juvenile levels | Prevention of typical memory loss |
| Neuropathological Impact | 2.4-fold increase in immature hippocampal neurons | Preserved neural cells without reduction of amyloid plaques |
Therapy Preserves Neurons but Does Not Clear Amyloid Plaques
Despite preserving cellular populations within the hippocampus, the experimental therapy did not alter the hallmark amyloid-beta plaques associated with Alzheimer’s pathology, Berliner Morgenpost reported. The therapeutic mechanism does not target or clear pathological protein aggregates. Instead, the intervention focuses on fortifying neuronal resilience, enhancing intercellular connectivity, and supporting structural maintenance. Investigators suggest that future therapeutic paradigms might combine these mRNA drops with agents specifically designed to clear amyloid plaques.
https://t.co/wuTKKO1OJFhttps://t.co/fmtsEeugfS
Major limits in applying these early results to people temper the findings. The observed efficacy remains strictly confined to murine models, and the testing cohorts comprised modest sample sizes ranging between six and ten animals per group. Comprehensive toxicological profiling, long-term safety evaluations, and precise pharmacokinetic mapping of spatial distribution within the central nervous system must occur prior to any human clinical trials.
Professor Greg Neely, Professor of Functional Genomics at the University of Sydney, leads a laboratory dedicated to the systematic functional annotation of the genome with a long-term objective of identifying genes and coding mutations that participate in major age-related and neurological diseases.
He is a member of the Charles Perkins Centre and the Centre for Drug Discovery Innovation. His funded research portfolio includes a National Health and Medical Research Council grant for a functional genomics approach to extend lifespan while preventing age-related cognitive decline, as well as projects investigating pain mechanisms through venom and CRISPR screening.
Consult a Doctor for Cognitive Decline Symptoms
Patients experiencing cognitive decline, memory impairment, or suspected dementia symptoms should avoid unverified prophylactic regimens and instead consult a qualified neurologist or primary care physician for evidence-based diagnostic evaluation and management. Professional medical intervention is warranted immediately if individuals experience rapid cognitive changes, acute confusion, or behavioral disturbances.
References
- University of Sydney research updates on mRNA delivery systems via the nasal mucosa.
- Scinexx science magazine coverage on neurogenesis markers in hippocampal tissue.
- Berliner Morgenpost and regional syndicate reporting on experimental Alzheimer’s interventions.